Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Claris Ventures
BioCentury | Mar 1, 2023
Management Tracks
C4’s Adam Crystal to head R&D at Tango
Plus: new CFO at BioArctic and updates from Sutro, Korro, BioAtla, Claris, Akoya and more
BioCentury | Jun 4, 2022
Emerging Company Profile
Heqet: regenerating heart muscle cells via the Hippo pathway
King’s College spinout is inducing cardiomyocyte regeneration via nanoparticle-delivered miRNA
BioCentury | May 20, 2022
Emerging Company Profile
Iama: treating autism by restoring chloride homeostasis
The Italian newco is selectively inhibiting NKCC1 to restore chloride regulation while avoiding side effects of non-selective inhibitors
BioCentury | May 17, 2022
Finance
Indaco adds to Italian ecosystem with launch of first dedicated biotech fund
Firm raises €95M at first close, with €150M target for Italian biotechs
BioCentury | May 13, 2022
Finance
Italy solves its biotech chicken-and-egg problem
New funds and infrastructure to support company creation in Italy could in turn attract more investors and entrepreneurs
BioCentury | May 9, 2022
Data Byte
Italian seed and series A financings since 2020
At least 12 Italian start-ups have attracted seed or series A funding since 2020, with Sofinnova and Claris the most active VCs
BioCentury | Mar 11, 2021
Deals
March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis
Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage
Items per page:
1 - 7 of 7